{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2023,2,13]],"date-time":"2023-02-13T14:28:52Z","timestamp":1676298532632},"reference-count":38,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2000,5,1]],"date-time":"2000-05-01T00:00:00Z","timestamp":957139200000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Current Science Inc"],"published-print":{"date-parts":[[2000,5]]},"DOI":"10.1007\/s11906-000-0018-y","type":"journal-article","created":{"date-parts":[[2007,5,24]],"date-time":"2007-05-24T04:54:28Z","timestamp":1179982468000},"page":"335-342","source":"Crossref","is-referenced-by-count":8,"title":["Treatment of hypertension in diabetes mellitus"],"prefix":"10.1007","volume":"2","author":[{"given":"Alejandro","family":"de la Sierra","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Luis Miguel","family":"Ruilope","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"18_CR1","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1161\/01.HYP.19.5.403","volume":"19","author":"M Epstein","year":"1992","unstructured":"Epstein M, Sowers J: Diabetes mellitus and hypertension. Hypertension 1992, 19:403\u2013418.","journal-title":"Hypertension"},{"key":"18_CR2","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1161\/01.HYP.23.2.145","volume":"23","author":"The National High Blood Pressure Education Program Working Group","year":"1994","unstructured":"The National High Blood Pressure Education Program Working Group: National High Blood Pressure Education Program Working Group report on hypertension in diabetes. Hypertension 1994, 23:145\u2013158.","journal-title":"Hypertension"},{"key":"18_CR3","first-page":"2336","volume-title":"Hypertension, Pathophysiology, Diagnosis, and Management.","author":"CE Mogensen","year":"1995","unstructured":"Mogensen CE: Management of the diabetic patient with elevated blood pressure and renal disease. Early screening and treatment programs: albuminuria and blood pressure. In Hypertension, Pathophysiology, Diagnosis, and Management. Edited by Laragh JH, Brenner BM. New York: Raven Press; 1995:2336\u20132365."},{"key":"18_CR4","doi-asserted-by":"crossref","first-page":"869","DOI":"10.1161\/01.HYP.26.6.869","volume":"26","author":"JR Sowers","year":"1995","unstructured":"Sowers JR, Epstein M: Diabetes mellitus and associated hypertension, vascular disease, and nephropathy. An update. Hypertension 1995, 26:869\u2013879.","journal-title":"Hypertension"},{"key":"18_CR5","doi-asserted-by":"crossref","first-page":"938","DOI":"10.1093\/ajh\/6.11.938","volume":"6","author":"PR Standley","year":"1993","unstructured":"Standley PR, Ali S, Bapna C, Sowers JR: Increased platelet cytosolic calcium responses to low density lipoprotein in type II diabetes with and without hypertension. Am J Hypertens 1993, 6:938\u2013943.","journal-title":"Am J Hypertens"},{"key":"18_CR6","doi-asserted-by":"crossref","first-page":"643","DOI":"10.1016\/0049-3848(92)90068-L","volume":"67","author":"F Carmassi","year":"1992","unstructured":"Carmassi F, Morale M, Puccetti R, et al.: Coagulation and fibrinolytic system impairment in insulin dependent diabetes mellitus. Thromb Res 1992, 67:643\u2013654.","journal-title":"Thromb Res"},{"key":"18_CR7","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1161\/01.HYP.20.2.253","volume":"20","author":"WA Hseuh","year":"1992","unstructured":"Hseuh WA, Anderson PW: Hypertension, the endothelial cell, and the vascular complications of diabetes mellitus. Hypertension 1992, 20:253\u2013263.","journal-title":"Hypertension"},{"key":"18_CR8","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1056\/NEJM199807233390404","volume":"339","author":"SM Haffner","year":"1998","unstructured":"Haffner SM, Lehto S, Ronnemaa T, et al.: Mortality from coronary heart disease in subjects with type 2 diabetes and in nondiabetic subjects with and without prior myocardial infarction. N Engl J Med 1998, 339:229\u2013234.","journal-title":"N Engl J Med"},{"key":"18_CR9","doi-asserted-by":"crossref","first-page":"1456","DOI":"10.1056\/NEJM199311113292004","volume":"329","author":"EJ Lewis","year":"1993","unstructured":"Lewis EJ, Hunsicker LG, Bain RP, Rohde RD, for the Collaborative Study Group: The effect of angiotensin converting enzyme inhibition on diabetic nephropathy: the Collaborative Study Group. N Engl J Med 1993, 329:1456\u20131462.","journal-title":"N Engl J Med"},{"key":"18_CR10","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1016\/S0140-6736(97)06209-0","volume":"351","author":"N Chatuverdi","year":"1998","unstructured":"Chatuverdi N, Sjolie AK, Stephenson JM, et al.: Effect of lisinopril on progression of retinopathy in normotensive people with type 1 diabetes. The EUCLID Study Group. EURODIAB Controlled Trial of Lisinopril in Insulin-Dependent Diabetes Mellitus. Lancet 1998, 351:28\u201331.","journal-title":"Lancet"},{"key":"18_CR11","doi-asserted-by":"crossref","first-page":"2413","DOI":"10.1001\/archinte.1997.00440420033005","volume":"157","author":"The Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure","year":"1997","unstructured":"The Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: The Sixth Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. Arch Intern Med 1997, 157:2413\u20132446.","journal-title":"Arch Intern Med"},{"key":"18_CR12","first-page":"151","volume":"17","author":"Guidelines Subcommittee","year":"1999","unstructured":"Guidelines Subcommittee: 1999 World Health Organization-International Society of Hypertension Guidelines for the Management of Hypertension. J Hypertens 1999, 17:151\u2013183.","journal-title":"J Hypertens"},{"key":"18_CR13","doi-asserted-by":"crossref","first-page":"569","DOI":"10.1038\/sj.jhh.1000917","volume":"13","author":"LE Ramsay","year":"1999","unstructured":"Ramsay LE, Williams B, Johnston GD, et al.: Guidelines for management of hypertension: report of the third working party of the British Hypertension Society. J Hum Hypertens 1999, 13:569\u2013592.","journal-title":"J Hum Hypertens"},{"key":"18_CR14","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1016\/S0140-6736(99)12323-7","volume":"355","author":"Heart Outcomes Prevention Evaluation (HOPE) Study Investigators","year":"2000","unstructured":"Heart Outcomes Prevention Evaluation (HOPE) Study Investigators: Efects of ramipril on cardiovascular and microvascular outcomes in people with diabetes mellitus: results of the HOPE study and MICRO-HOPE substudy. Lancet 2000, 355:253\u2013259. Treatment with the ACE inhibitor ramipril reduces the risk of myocardial infarction, stroke, and cardiovascular death in diabetic patients with previous cardiovascular disease or associated cardiovascular risk factors.","journal-title":"Lancet"},{"issue":"suppl 2","key":"18_CR15","doi-asserted-by":"crossref","first-page":"S63","DOI":"10.1097\/00004872-199715022-00005","volume":"15","author":"LM Ruilope","year":"1997","unstructured":"Ruilope LM, Garc\u00efa-Robles R: How far should blood pressure be reduced in diabetic hypertensive patients? J Hypertens 1997, 15(suppl 2):S63-S65.","journal-title":"J Hypertens"},{"key":"18_CR16","doi-asserted-by":"crossref","first-page":"1755","DOI":"10.1016\/S0140-6736(98)04311-6","volume":"351","author":"L Hansson","year":"1998","unstructured":"Hansson L, Zanchetti A, Carruthers SG, et al., for the HOT Study Group: Effects of intensive blood-pressure lowering and lowdose aspirin in patients with hypertension: principal results of the Hypertension Optimal Treatment (HOT) randomised trial. Lancet 1998, 351:1755\u20131762. Intensive blood pressure lowering with antihypertensive treatement based on the calcium channel blocker felodipine reduces major cardiovascular events and cardiovascular mortality in diabetic hypertensive patients.","journal-title":"Lancet"},{"key":"18_CR17","doi-asserted-by":"crossref","first-page":"703","DOI":"10.1136\/bmj.317.7160.703","volume":"317","author":"UK Prospective Diabetes Study Group","year":"1998","unstructured":"UK Prospective Diabetes Study Group: Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38. BMJ 1998, 317:703\u2013712. Tight blood pressure control in hypertensive type 2 diabetics protects against diabetes-related macrovascular and microvascular complications.","journal-title":"BMJ"},{"key":"18_CR18","doi-asserted-by":"crossref","first-page":"1886","DOI":"10.1001\/jama.1996.03540230036032","volume":"276","author":"JD Curb","year":"1996","unstructured":"Curb JD, Pressel SL, Cutler JA, et al.: Effect of diuretic-based antihypertensive treatment on cardiovascular disease risk in older diabetic patients with isolated systolic hypertension. Systolic Hypertension in the Elderly Program Cooperative Research Group. JAMA 1996, 276:1886\u20131892.","journal-title":"JAMA"},{"key":"18_CR19","doi-asserted-by":"crossref","first-page":"1751","DOI":"10.1016\/S0140-6736(99)10327-1","volume":"354","author":"L Hansson","year":"1999","unstructured":"Hansson L, Lindholm LH, Ekbom T, et al.: for the STOPHypertension-2 Study Group. Randomised trial of old and new antihypertensive drugs in elderly patients: cardiovascular mortality and morbidity in the Swedish Trial in Old Patients with Hypertension-2 Study. Lancet 1999, 354:1751\u20131756. Conventional (diuretics and\/or b-blockers) or new drugs (calcium antagonists or ACE inhibitors) are equally effective in preventing cardiovascular disease in elderly patients with hypertension.","journal-title":"Lancet"},{"key":"18_CR20","doi-asserted-by":"crossref","first-page":"713","DOI":"10.1136\/bmj.317.7160.713","volume":"317","author":"UK Prospective Diabetes Study Group","year":"1998","unstructured":"UK Prospective Diabetes Study Group: Efficacy of atenolol and captopril in reducing risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 39. BMJ 1998, 317:713\u2013720. Captopril and atenolol are equally effective in reducing diabetesrelated complications in type 2 diabetic hypertensive patients with tight blood pressure control (\u00a3 150\/85).","journal-title":"BMJ"},{"key":"18_CR21","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1007\/s11906-999-0025-6","volume":"1","author":"WH Birkenh\u00e4ger","year":"1999","unstructured":"Birkenh\u00e4ger WH, Staessen JA: Treatment of diabetic patients with hypertension. Curr Hypertens Rep 1999, 1:225\u2013231.","journal-title":"Curr Hypertens Rep"},{"key":"18_CR22","doi-asserted-by":"crossref","first-page":"645","DOI":"10.1056\/NEJM199803053381003","volume":"338","author":"RO Estacio","year":"1998","unstructured":"Estacio RO, Jeffers BW, Hiatt WR, et al.: The effect of nisoldipine as compared with enalapril on cardiovascular outcomes in patients with non-insulin-dependent diabetes and hypertension. N Engl J Med 1998, 338:645\u2013652.","journal-title":"N Engl J Med"},{"key":"18_CR23","doi-asserted-by":"crossref","first-page":"597","DOI":"10.2337\/diacare.21.4.597","volume":"21","author":"P Tatti","year":"1998","unstructured":"Tatti P, Pahor M, Byington RP, et al.: Outcome results of the Fosinopril versus Amlodipine Cardiovascular Events Randomized Trial (FACET) in patients with hypertension and NIDDM. Diabetes Care 1998, 21:597\u2013603.","journal-title":"Diabetes Care"},{"key":"18_CR24","doi-asserted-by":"crossref","first-page":"677","DOI":"10.1056\/NEJM199903043400902","volume":"340","author":"J Tuomilehto","year":"1999","unstructured":"Tuomilehto J, Rastenyte D, Birkenh\u00e4ger WH, et al. for the Systolic Hypertension in Europe Trial Investigators: Effects of calcium-channel blockade in older patients with diabetes and systolic hypertension. N Engl J Med 1999, 340:677\u2013684. Post hoc analysis of the SYST-EUR trial comparing diabetic and nondiabetic patients with isolated systolic hypertension showing that nitrendipine-based treatment decreases cardiovascular mortality only in the subgroup of diabetics.","journal-title":"N Engl J Med"},{"key":"18_CR25","doi-asserted-by":"crossref","first-page":"611","DOI":"10.1016\/S0140-6736(98)05012-0","volume":"353","author":"L Hansson","year":"1999","unstructured":"Hansson L, Lindholm LH, Niskanen L, et al., for the Captopril Prevention Project (CAPPP) Study Group: Effect of angiotensin-converting-enzyme inhibition compared with conventional therapy on cardiovascular morbidity and mortality in hypertension: the Captopril Prevention Project (CAPPP) randomised trial. Lancet 1999, 353:611\u2013616. Captopril, compared with conventional therapy (diuretics and\/or b-blockers), is more effective in decreasing the risk of myocardial infarction in hypertensive diabetic patients.","journal-title":"Lancet"},{"key":"18_CR26","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1161\/01.HYP.22.3.339","volume":"22","author":"M Burnier","year":"1993","unstructured":"Burnier M, Rutschmann B, Nussberger J, et al.: Salt-dependent renal effects of an angiotensin II antagonist in healthy subjects. Hypertension 1993, 22:339\u2013347.","journal-title":"Hypertension"},{"key":"18_CR27","doi-asserted-by":"crossref","first-page":"602","DOI":"10.1161\/01.HYP.25.4.602","volume":"25","author":"M Burnier","year":"1995","unstructured":"Burnier M, Hagman B, Nussberger J, et al.: Short-term and sustained renal effects of angiotensin II receptor blockade in healthy subjects. Hypertension 1995, 25:602\u2013609.","journal-title":"Hypertension"},{"key":"18_CR28","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1042\/cs0900205","volume":"90","author":"F Schmitt","year":"1996","unstructured":"Schmitt F, Natov S, Martinez F, et al.: Renal effects of angiotensin II receptor blockade and angiotensin convertase inhibition in man. Clin Sci 1996, 90:205\u2013213.","journal-title":"Clin Sci"},{"key":"18_CR29","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1161\/01.HYP.30.2.240","volume":"30","author":"DA Price","year":"1997","unstructured":"Price DA, De Oliveira JM, Fisher NDL, Hollenberg NK: Renal hemodynamic response to an angiotensin II antagonist, eprosartan, in healthy man. Hypertension 1997, 30:240\u2013246.","journal-title":"Hypertension"},{"key":"18_CR30","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1097\/00005344-199504000-00001","volume":"25","author":"JK Doig","year":"1995","unstructured":"Doig JK, MacFadyen RJ, Sweet CS, Reid JL: Haemodynamic and renal responses to oral losartan potassium during salt depletion or salt repletion in normal human volunteers. J Cardiovasc Pharmacol 1995, 25:511\u2013517.","journal-title":"J Cardiovasc Pharmacol"},{"key":"18_CR31","first-page":"117","volume":"5","author":"M Kawabata","year":"1994","unstructured":"Kawabata M, Takabatake T, Ohta H, et al.: Effects of an angiotensin II receptor antagonist, TCV-116, on renal haemodynamics in essential hypertension. Blood Press 1994, 5(suppl):117\u2013121.","journal-title":"Blood Press"},{"issue":"suppl 1","key":"18_CR32","first-page":"S8","volume":"43","author":"CM Erley","year":"1995","unstructured":"Erley CM, Bader B, Scheu M, et al.: Renal hemodynamics in essntial hypertensives treated with losartan. Clin Nephrol 1995, 43(suppl 1):S8-S11.","journal-title":"Clin Nephrol"},{"key":"18_CR33","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1097\/00005344-199608000-00012","volume":"28","author":"JP Fauvel","year":"1996","unstructured":"Fauvel JP, Velon S, Berra N, et al.: Effects of losartan on renal function in patients with essential hypertension. J Cardiovasc Pharmacol 1996, 28:259\u2013263.","journal-title":"J Cardiovasc Pharmacol"},{"issue":"suppl 2","key":"18_CR34","first-page":"19","volume":"12","author":"S Nielsen","year":"1997","unstructured":"Nielsen S, Dollerup J, Nielsen B, et al.: Losartan reduces albuminuria in patients with essentil hypertension. An enalapril controlled 3 months study. Nephrol Dial Transplant 1997, 12(suppl 2):19\u201323.","journal-title":"Nephrol Dial Transplant"},{"key":"18_CR35","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1159\/000169075","volume":"17","author":"JC Chan","year":"1997","unstructured":"Chan JC, Critchley JA, Tomlinson B, et al.: Antihypertensive and anti-albuminuric effects of losartan potassium and felodipine in Chinese elderly hypertensive patients with or without non-insulin-dependent diabetes mellitus. Am J Nephrol 1997, 17:72\u201380.","journal-title":"Am J Nephrol"},{"key":"18_CR36","doi-asserted-by":"crossref","first-page":"1963","DOI":"10.1093\/ndt\/10.4.497","volume":"10","author":"RT Gansevoort","year":"1995","unstructured":"Gansevoort RT, Sluiter W, Hemmelder MH, et al.: Antiproteinuric effect of blood pressure lowering angents: a meta-analysis of comparative trials. Nephrol Dial Transplant 1995, 10:1963\u20131974.","journal-title":"Nephrol Dial Transplant"},{"key":"18_CR37","doi-asserted-by":"crossref","first-page":"684","DOI":"10.1161\/01.HYP.31.2.684","volume":"31","author":"R Toto","year":"1998","unstructured":"Toto R, Shultz P, Raij L, et al.: Efficacy and tolerability of losartan in hypertensive patients with renal impairment. Hypertension 1998, 31:684\u2013691.","journal-title":"Hypertension"},{"key":"18_CR38","first-page":"S218","volume":"63","author":"MP O\u2019Donnell","year":"1997","unstructured":"O\u2019Donnell MP, Crary GS, Oda H, et al.: Irbesartan lowers blood pressure and ameliorates renal injury in experimental non-insulin-dependent diabetes mellitus. Kidney Int 1997, 63(suppl):S218-S220.","journal-title":"Kidney Int"}],"container-title":["Current Hypertension Reports"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11906-000-0018-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s11906-000-0018-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11906-000-0018-y","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,6,2]],"date-time":"2019-06-02T00:15:56Z","timestamp":1559434556000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s11906-000-0018-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2000,5]]},"references-count":38,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2000,5]]}},"alternative-id":["18"],"URL":"https:\/\/doi.org\/10.1007\/s11906-000-0018-y","relation":{},"ISSN":["1522-6417","1534-3111"],"issn-type":[{"value":"1522-6417","type":"print"},{"value":"1534-3111","type":"electronic"}],"subject":[],"published":{"date-parts":[[2000,5]]}}}